open access

Vol 13, No 4 (2006): Folia Cardiologica
Original articles
Published online: 2006-04-24
Get Citation

High doses of simvastatin in ACS decrease serum PDGF levels without influencing immune activation

Katarzyna Mizia-Stec, Zbigniew Gąsior, Barbara Zahorska-Markiewicz, Joanna Janowska, Magdalena Mizia, Piotr Pysz, Michał Holecki, Grażyna Knauer-Janicka
Folia Cardiol 2006;13(4):326-330.

open access

Vol 13, No 4 (2006): Folia Cardiologica
Original articles
Published online: 2006-04-24

Abstract

Background: The positive effects of statin therapy in acute coronary syndromes (ACS) may result from their anti-inflammatory and anti-thrombotic effects. The aim of the study was to compare the influence of standard and high-dose statin therapies in ACS on the serum markers of immune and platelet activation.
Material and methods: We examined 44 patients with ACS randomised into two groups: Group S(+) - 22 patients with ACS who were administered high doses of simvastatin (80 mg per day) over a period of one month from a cardiac event; Group S(–) - 22 patients with ACS treated by standard doses of statins. In all patients successful percutaneous coronary interventions (PCI) were performed. Laboratory analyses were performed at the baseline on the 7th and 30th days from an ACS and involved the following: platelet-derived growth factor (PDGF), tumour necrosis factor (TNF) alpha, soluble forms of TNF receptor (sTNFR 1 and 2), Interleukin-2 (IL-2), and IL-10.
Results: During a one-month follow-up we found no difference between clinical data and the baseline levels of the assessed markers in the groups examined. There were no differences in the consecutive measurements of TNF-a, sTNFR1, sTNFR 2, IL-2, and IL-10 levels. Serum concentrations of PDGF were significantly lower on the 7th and 30th days in group S(+) (7th: 6111 ± 1834 pg/ml, p = 0.037; 30th: 5735 ± 1089 pg/ml, p = 0.016, respectively) in comparison to group S(–) (7th: 7292 ± 1952 pg/ml; 30th: 7034 ± 2008 pg/ml, respectively).
Conclusions: High doses of simvastatin administered over a period of one month following an acute coronary syndrome were associated with a significant decrease in serum PDGF levels without influence on the activation of serum immune markers.

Abstract

Background: The positive effects of statin therapy in acute coronary syndromes (ACS) may result from their anti-inflammatory and anti-thrombotic effects. The aim of the study was to compare the influence of standard and high-dose statin therapies in ACS on the serum markers of immune and platelet activation.
Material and methods: We examined 44 patients with ACS randomised into two groups: Group S(+) - 22 patients with ACS who were administered high doses of simvastatin (80 mg per day) over a period of one month from a cardiac event; Group S(–) - 22 patients with ACS treated by standard doses of statins. In all patients successful percutaneous coronary interventions (PCI) were performed. Laboratory analyses were performed at the baseline on the 7th and 30th days from an ACS and involved the following: platelet-derived growth factor (PDGF), tumour necrosis factor (TNF) alpha, soluble forms of TNF receptor (sTNFR 1 and 2), Interleukin-2 (IL-2), and IL-10.
Results: During a one-month follow-up we found no difference between clinical data and the baseline levels of the assessed markers in the groups examined. There were no differences in the consecutive measurements of TNF-a, sTNFR1, sTNFR 2, IL-2, and IL-10 levels. Serum concentrations of PDGF were significantly lower on the 7th and 30th days in group S(+) (7th: 6111 ± 1834 pg/ml, p = 0.037; 30th: 5735 ± 1089 pg/ml, p = 0.016, respectively) in comparison to group S(–) (7th: 7292 ± 1952 pg/ml; 30th: 7034 ± 2008 pg/ml, respectively).
Conclusions: High doses of simvastatin administered over a period of one month following an acute coronary syndrome were associated with a significant decrease in serum PDGF levels without influence on the activation of serum immune markers.
Get Citation

Keywords

platelet-derived growth hormone; cytokines; acute coronary syndrome

About this article
Title

High doses of simvastatin in ACS decrease serum PDGF levels without influencing immune activation

Journal

Cardiology Journal

Issue

Vol 13, No 4 (2006): Folia Cardiologica

Pages

326-330

Published online

2006-04-24

Bibliographic record

Folia Cardiol 2006;13(4):326-330.

Keywords

platelet-derived growth hormone
cytokines
acute coronary syndrome

Authors

Katarzyna Mizia-Stec
Zbigniew Gąsior
Barbara Zahorska-Markiewicz
Joanna Janowska
Magdalena Mizia
Piotr Pysz
Michał Holecki
Grażyna Knauer-Janicka

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl